Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 4/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | GUSB | P08236 | 6/20 | 0.71 |
| ▸ | TNKS | O95271 | 12/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 11/20 | 0.64 |
| ▸ | PARP1 | P09874 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | F11 | P03951 | 1/20 | 0.58 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23743266 | 0.88 | CYP1B1 (0.78) | CYP1B1CYP1A1CYP1A2GUSBTNKS | |
| SCHEMBL15232132 | 0.87 | CYP1B1 (0.77) | CYP1B1CYP1A1CYP1A2GUSBTNKS | |
| SCHEMBL23743249 | 0.83 | CYP1B1 (0.71) | CYP1B1CYP1A1CYP1A2GUSBTNKS | |
| SCHEMBL11831977 | 0.83 | GUSB (1.00) | CYP1B1CYP1A1CYP1A2GUSBTNKS | |
| SCHEMBL10061954 | 0.82 | CYP1A1 (0.69) | CYP1B1CYP1A1CYP1A2PARP1NPC1 | |
| SCHEMBL19566149 | 0.81 | TNKS (0.74) | CYP1B1CYP1A1CYP1A2GUSBTNKS | |
| SCHEMBL348494 | 0.81 | GUSB (0.73) | CYP1B1CYP1A1CYP1A2GUSBTNKS | |
| SCHEMBL6885282 | 0.81 | TNKS (0.93) | CYP1B1CYP1A1GUSBTNKSTNKS2 | |
| SCHEMBL23743193 | 0.80 | CYP1B1 (0.80) | CYP1B1CYP1A1CYP1A2GUSBTNKS | |
| SCHEMBL31238676 | 0.80 | TNKS (0.76) | CYP1B1CYP1A1CYP1A2GUSBTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246109-A1 | POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2021-08-12 | — | — | US | disclosed |
| US-9611256-B2 | Alkyne-, azide- and triazole-containing flavonoids as modulators for multidrug resistance in cancers | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2017-04-04 | — | — | US | disclosed |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | ABCG2, ABCB1, ABCC1 | CYP1B1 35/4885CYP1A1 34/4885CYP1A2 100/4885 |
| US-20210246109-A1 | POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP1B1, CYP27A1 | CYP1B1 2/4885CYP1A1 6/4885CYP1A2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.